35418-05-4

Basic information

• Product Name: 3-NITROCINNAMOYL CHLORIDE
• Synonyms: 3-NITROCINNAMOYL CHLORIDE;3-(3-NITROPHENYL)-2-PROPENOYLCHLORIDE;3-(3-NITROPHENYL)-2-PROPENOYLHLORIDE
• CAS NO: 35418-05-4
• Molecular Formula: C₉H₆ClNO₃
• Molecular Weight: 211.6
• Mol File: 35418-05-4.mol
• Article Data: 47

Chemical Properties

• Boiling Point: 342.9°Cat760mmHg
• Flash Point: 161.2°C
• Appearance: /
• Density: 1.403g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.629
• CAS DataBase Reference: 3-NITROCINNAMOYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-NITROCINNAMOYL CHLORIDE(35418-05-4)
• EPA Substance Registry System: 3-NITROCINNAMOYL CHLORIDE(35418-05-4)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 35418-05-4(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H6ClNO3/c10-9(12)5-4-7-2-1-3-8(6-7)11(13)14/h1-6H/b5-4+

Upstream product

• 99-61-6 3-nitro-benzaldehyde 
• 555-68-0 (E)-3-Nitrocinnamic acid 
• 555-68-0 m-Nitrocinnamic Acid 

Downstream Products

• 86223-76-9 1-(3-Nitrophenyl)-7-methoxy-hepta-1,6-dien-4-in-3-on 
• 134835-05-5 N-(3-Nitrocinnamoyl)-N-(2-chlorophenyl)hydroxylamine 
• 134835-10-2 N-(3-Nitrocinnamoyl)-N-(2,5-dibromophenyl)hydroxylamine 
• 100098-62-2 (E)-3-nitro-N-(2-hydroxy-1,1-dimethylethyl) cinnamamide 
• 160913-14-4 N,N-bis-(2-hydroxyethyl)-3-(3'-nitrophenyl)-2-propenamide 

Relevant articles and documents

Radiosensitization of human pancreatic cancer by piperlongumine analogues

Radiotherapy is commonly used to treat advanced pancreatic cancers and can improve survival by 2 months in combination with gemcitabine. However, prognosis and survival improvement remain unsatisfactory, and effective therapies are urgently needed. Piperlongumine has been demonstrated to have therapeutic potentials against various cancers. In this study, we synthesized a series of piperlongumine derivatives and provided evidence that piperlongumine derivatives could be used as effective radiosensitizers in pancreatic cancer. Two compounds enhanced the radiosensitivity of Panc-1 and SW1990 cells. In a pancreatic bi-flank xenograft tumor model, they significantly inhibited tumor growth. Piperlongumine derivatives could induce reactive oxygen species (ROS) expression and regulate the Keap1-Nrf2 protective pathway with enhancement of radiation-induced DNA damage, G2/M-phase cell cycle arrest, and apoptosis. Collectively, our data offer a proof of concept for the use of piperlongumine derivatives as a novel class of radiosensitizers for the treatment of pancreatic cancer.

New coumarin/sulfocoumarin linked phenylacrylamides as selective transmembrane carbonic anhydrase inhibitors: Synthesis and in-vitro biological evaluation

Two novel series of phenylacrylamide linked coumarins and sulfocoumarins (6a-p, 8a-i, and 14a-g) were synthesized and evaluated against four physiologically relevant human carbonic anhydrases (hCAs, EC 4.2.1.1), isoforms hCA I, hCA II, hCA IX and hCA XII for their inhibitory action. All new compounds when screened for carbonic anhydrase inhibitory activity have shown selective inhibition towards the tumor associated isoforms hCA IX and XII over CA I and II, with inhibition constants in the submicromolar to low nanomolar range. Compound 6b and 14g exhibited significant inhibition with low nanomolar potency against hCA IX, whereas 6k was effective against hCA XII. Compounds 6b, 14g and 6k may be considered as lead molecules for future development of cancer therapeutics based on a novel mechanism of action.

INHIBITORS OF CBL-B AND METHODS OF USE THEREOF

Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo.